



May 8, 2023

Company Name: GNI Group Ltd.  
Representative: Director, Representative Executive Officer,  
President and CEO  
Ying Luo, PhD  
(Security Code: 2160, TSE Growth)  
Contact Person: Director, Investor Relations  
Akihiro Nakano  
(TEL. 03-6214-3600)

**(Update to a previous disclosure) Catalyst Biosciences, Inc. files 8-K with SEC on their Nasdaq listing condition**

GNI Group Ltd., (TSE Growth listed code: 2160; “the Company” or “we”) hereby announces that Catalyst Biosciences, Inc. ("CBIO"), an equity method affiliate of GNI Group Inc. and listed on Nasdaq in the United States, has filed the following document with the U.S. Securities and Exchange Surveillance Commission ("SEC").

[https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036123023200/brhc20052574\\_8k.htm](https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036123023200/brhc20052574_8k.htm)

At this time, the above disclosure by CBIO will have no impact on our consolidated financial figures. However, as mentioned in a previous disclosure by CBIO, our transaction with CBIO is conditional on CBIO maintaining its listing on Nasdaq, and we will closely monitor CBIO's situation and fully support CBIO to maintain its Nasdaq listing status.

---

**About GNI Group Ltd.:**

GNI Group Ltd. is a global healthcare company listed on the Growth Market of the Tokyo Stock Exchange, and is engaged in drug discovery, development of pharmaceuticals and biomaterials, clinical trials, manufacturing, sales, and consulting services to support the introduction of medical devices to Japan across the US, China, and Japan. For more information, please visit our website below:

<https://www.gnipharma.com/>

**About Catalyst Biosciences, Inc.:**

CBIO is a biopharmaceutical company with expertise in protease engineering. Prior to ceasing research and development activities in March 2022, CBIO had several protease assets that may address unmet medical needs in disorders of the complement or coagulation systems. CBIO is exploring several strategic alternatives to monetize CBIO's legacy assets and is focused on distributing its available cash, after paying or reserving for its obligations and liabilities, to stockholders in 2022. For more information, please visit Catalyst Biosciences' website below:

<https://www.catalystbiosciences.com/>

This material contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. ("the Company"). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as "believe," "plan," "strategy," "expect," "forecast," "possibility" and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of the Company must be based wholly on the information contained in the preliminary offering circular issued or to be issued by the Company in connection with any such offer and not on the contents hereof.